How Analysts Feel About Advaxis, Inc. (ADXS) After Reaching 1 Year Low?

September 17, 2017 - By Winifred Garcia

Investors sentiment decreased to 1.39 in 2016 Q4. Its down 0.33, from 1.72 in 2016Q3. It fall, as 13 investors sold Advaxis, Inc. shares while 20 reduced holdings. 13 funds opened positions while 33 raised stakes. 22.36 million shares or 1.90% less from 22.79 million shares in 2016Q3 were reported.
Sectoral Asset Management has 0.55% invested in Advaxis, Inc. (NASDAQ:ADXS) for 690,074 shares. Parametric Port Associates Ltd, a Washington-based fund reported 40,027 shares. The New York-based Broadfin Capital Ltd has invested 1.21% in Advaxis, Inc. (NASDAQ:ADXS). Alliancebernstein L P has 0% invested in Advaxis, Inc. (NASDAQ:ADXS). Tiaa Cref Management Limited Liability Company reported 128,798 shares or 0% of all its holdings. Vanguard Inc invested in 0% or 1.52M shares. Blackrock holds 2,572 shares or 0% of its portfolio. Blackrock Fund Advsr has 0% invested in Advaxis, Inc. (NASDAQ:ADXS). Pacad invested 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS). Voya Mngmt Lc holds 0% or 14,637 shares in its portfolio. Blackrock Inv Ltd reported 141,941 shares or 0% of all its holdings. Vident Invest Advisory Lc has 90,785 shares for 0.08% of their portfolio. Ny State Common Retirement Fund accumulated 0% or 34,200 shares. Bnp Paribas Arbitrage Sa, a New York-based fund reported 603 shares. Zacks Mngmt has 12,317 shares for 0% of their portfolio.

Since March 31, 2017, it had 0 insider purchases, and 1 sale for $20,221 activity. PETIT ROBERT had sold 2,454 shares worth $20,221 on Friday, March 31.

The stock of Advaxis, Inc. (NASDAQ:ADXS) hit a new 52-week low and has $4.47 target or 7.00 % below today’s $4.81 share price. The 6 months bearish chart indicates high risk for the $197.53 million company. The 1-year low was reported on Sep, 17 by If the $4.47 price target is reached, the company will be worth $13.83 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 2.43% or $0.12 on September 15, reaching $4.81. About 1.11M shares traded or 106.02% up from the average. Advaxis, Inc. (NASDAQ:ADXS) has risen 11.01% since September 17, 2016 and is uptrending. It has underperformed by 5.69% the S&P500.

Analysts await Advaxis, Inc. (NASDAQ:ADXS) to report earnings on January, 8. After $-0.80 actual earnings per share reported by Advaxis, Inc. for the previous quarter, Wall Street now forecasts -30.00 % EPS growth.

Advaxis, Inc. (NASDAQ:ADXS) Ratings Coverage

Among 4 analysts covering Advaxis (NASDAQ:ADXS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Advaxis had 6 analyst reports since September 11, 2015 according to SRatingsIntel. On Thursday, July 6 the stock rating was maintained by Cantor Fitzgerald with “Buy”. As per Wednesday, June 14, the company rating was maintained by H.C. Wainwright. The company was maintained on Wednesday, May 31 by Cantor Fitzgerald. Guggenheim initiated the shares of ADXS in report on Friday, September 11 with “Buy” rating. The firm has “Buy” rating given on Monday, June 12 by Cantor Fitzgerald. Barclays Capital initiated Advaxis, Inc. (NASDAQ:ADXS) on Tuesday, September 22 with “Overweight” rating.

More recent Advaxis, Inc. (NASDAQ:ADXS) news were published by: which released: “Here’s Why Advaxis, Inc. Stock Is Getting Pummeled Today” on September 12, 2017. Also published the news titled: “Mid-Day Market Update: Advaxis Drops Following Q3 Results; Aethlon Medical …” on September 12, 2017.‘s news article titled: “Advaxis Reports Business Update and Third Quarter 2017 Results” with publication date: September 11, 2017 was also an interesting one.

Advaxis, Inc. is a clinical-stage biotechnology firm focused on the discovery, development and commercialization of Listeria monocytogenes -Listeriolysin O (LLO) cancer immunotherapies. The company has market cap of $197.53 million. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. It currently has negative earnings. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.